 Raised approximately 56.3 million of gross proceeds from a follow-on public offering of common stock in early July to provide funding for clinical development activities After follow-on offering, Celcuity had approximately 94.4 million of cash on hand Expanded clinical development and clinical operations capabilities with appointment of two new senior executives and the addition of other key team members In a Phase 1 study evaluating gedatolisib combined with paclitaxel and carboplatin, 65 of patients 1117 had an objective response, including three complete responses Management to host webcast and conference call today, August 9, 2021, at 4:30 p.m. ET 1:30 p.m. 